Emcure Pharma Ahmedabad oncology facility concludes USFDA inspection with no observations
Pune: Emcure Pharma has announced that the United States Food and Drug Administration (USFDA) has concluded a Pre-Approval Inspection (PAI) at the Company's manufacturing facility (Oncology) located at G.I.D.C., Taluka - Sanand, Ahmedabad – 382110, Gujarat, without issuance of Form 483 (zero observations).
The inspection was conducted from June 30, 2025 to July 08, 2025.
Read also: Emcure Pharma incorporates new wholly-owned subsidiary Emcure Wellness
Established in 1981, Emcure Pharmaceuticals Ltd. is an Indian pharma company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products. Emcure is an R&D driven company that develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas. Emcure is present in 70+ countries globally including Europe and Canada.
Read also: Emcure Pharma to acquire remaining stake in arm Zuventus Healthcare
